User:Mr. Ibrahem/Fluvoxamine
 | |
 | |
| Clinical data | |
|---|---|
| Trade names | Luvox, Faverin, Fluvoxin, others |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a695004 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | By mouth |
| Drug class | Selective serotonin reuptake inhibitor (SSRI) |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 53% (90% confidence interval: 44–62%)[2] |
| Protein binding | 77–80%[2][3] |
| Metabolism | Hepatic (via cytochrome P450 enzymes. Mostly via oxidative demethylation)[2] |
| Elimination half-life | 12–13 hours (single dose), 22 hours (repeated dosing)[2] |
| Excretion | Kidney (98%; 94% as metabolites, 4% as unchanged drug)[2] |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C15H21F3N2O2 |
| Molar mass | 318.335 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Fluvoxamine, sold under the brand name Luvox among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class.[5] It is used primarily for the treatment of obsessive–compulsive disorder (OCD).[5] Other uses include depression, bulemia, and anxiety disorders, such as panic disorder, social anxiety disorder, and post-traumatic stress disorder.[6][8][9] It is taken by mouth.[5]
Common side effects include nausea, sleepiness, sexual dysfunction, sweating, and agitation.[5] Other side effects include an increased risk of suicide in those under the age of 25 and liver problems.[5][6] Use during pregnancy is of unclear safety.[5] Use of fluvoxamine is not a requirement to stop breastfeeding.[7]
Fluvoxamine was approved for medical use in the United States in 1994.[5] It is on the World Health Organization's List of Essential Medicines as an alternative to fluoxetine.[10] It is available as a generic medication.[6] In the United Kingdom it costs the NHS about 18 pounds per month for the typical dose of 100 mg per day as of 2020.[6] This amount in the United States costs about 15 USD as of 2021.[11]
References[edit]
- ^ a b Use During Pregnancy and Breastfeeding
- ^ a b c d e "Product Information Luvox". TGA eBusiness Services. Abbott Australasia Pty Ltd. 15 January 2013. Archived from the original on 9 October 2017. Retrieved 21 October 2013.
- ^ van Harten J (March 1993). "Clinical pharmacokinetics of selective serotonin reuptake inhibitors". Clinical Pharmacokinetics. 24 (3): 203–20. doi:10.2165/00003088-199324030-00003. PMID 8384945. S2CID 84636672.
- ^ "Luvox". ChemSpider. Royal Society of Chemistry. Archived from the original on 15 November 2013. Retrieved 21 October 2013.
- ^ a b c d e f g h i "FluvoxaMINE Monograph for Professionals". Drugs.com. Archived from the original on 8 May 2021. Retrieved 14 April 2021.
- ^ a b c d e BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 384. ISBN 978-0-85711-369-6.
- ^ a b "Fluvoxamine use while Breastfeeding". Drugs.com. Archived from the original on 8 May 2021. Retrieved 15 April 2021.
- ^ Figgitt DP, McClellan KJ (October 2000). "Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders". Drugs. 60 (4): 925–54. doi:10.2165/00003495-200060040-00006. PMID 11085201.
- ^ Irons J (December 2005). "Fluvoxamine in the treatment of anxiety disorders". Neuropsychiatric Disease and Treatment. 1 (4): 289–99. PMC 2424117. PMID 18568110.
- ^ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
- ^ "Fluvoxamine Prices, Coupons & Savings Tips". GoodRx. Archived from the original on 8 May 2021. Retrieved 15 April 2021.